title: Factors affecting outcomes in colonoscopy.
abstract: There are many factors that influence successful outcomes in colonoscopy. The aims of this study were to evaluate these factors and determine ways to improve outcomes. All participants (N=229) who underwent planned colonoscopy between July and September 2004 were retrospectively included. Participants included 118 men and 111 women with a mean age of 59 years. Completion rate was 92%. Reasons of failure included poor bowel preparation (2.2%, p< .025), bowel looping (2.2%, p< .025), participant discomfort (1.3%), and obstructing lesion (1.3%). Mean midazolam dose was 3.8 mg. Three participants (1.3%) had midazolam alone, and all had complete colonoscopy. One hundred thirty-three participants (60.7%) had additional meperidine, with a completion rate of 94%. Eighty three participants (37.9%) had additional meperidine and Buscopan, with a completion rate reduced to 89.2%. There was no correlation between sedatives used and completion rate. Completion rate of colonoscopy in our unit was acceptable at 92%. A combination of midazolam and meperidine gave the best completion rates (94%). The two main reasons for incompletion were poor bowel preparation and excessive bowel looping.
authors.affiliation: West Midlands, University Hospitals Coventry, Department of Surgery, Walsgrave, United Kingdom.
authors.forename: Seema
authors.initials: S
authors.lastname: Selehi
authors.forename: Edmund
authors.initials: E
authors.lastname: Leung
authors.forename: Ling
authors.initials: L
authors.lastname: Wong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use; D002086:Butylscopolammonium Bromide / Q000009:adverse effects / Q000627:therapeutic use; D002951:Citrates; D003113:Colonoscopy / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D016292:Procedural Sedation / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D054368:Laxatives / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008485:Medical Audit; D008614:Meperidine / Q000009:adverse effects / Q000627:therapeutic use; D008874:Midazolam / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D009942:Organometallic Compounds; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010847:Picolines / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012676:Senna Extract / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000701:Analgesics, Opioid; D002951:Citrates; D006993:Hypnotics and Sedatives; D054368:Laxatives; D018727:Muscarinic Antagonists; D009942:Organometallic Compounds; D010847:Picolines; D002086:Butylscopolammonium Bromide; D012676:Senna Extract; D008614:Meperidine; C005701:picosulfate sodium; D008874:Midazolam